For the in vitro determination of Oncostatin M in serum, plasma, and stool
Oncostatin M (OSM), a member of the IL-6 cytokine family, plays a role in various homeostatic and pathophysiological processes. OSM promotes tissue repair and remodelling, but also regulates growth of different cancer cells. Up-regulation of OSM promotes skin and lung inflammation, atherosclerosis as well as several forms of cancer. Patients with inflammatory bowel diseases (IBD) are often treated with anti-TNFα therapy. However, 40 % of patients do not respond to TNFα inhibitors at all (primary non-response) or develop therapeutic resistance over time (secondary non-response). Besides its other functions, OSM and its receptor OSMR are also involved in maintaining inflammation in the gut. Both are up-regulated in the mucosa of IBD patients and influence especially the later stages of the inflammatory response. In addition, high levels of OSM before anti-TNFα therapy correlate with an increased risk of primary non-response. The amount of OSM in the gut therefore seems to be a predictive biomarker of anti-TNFα treatment failure in IBD patients, and could be useful as a diagnostic tool for early stratification of patients expected to benefit from treatment.This assay is a Sandwich ELISA for 100 µl serum/plasma or prepared stool sample.
For research use only!
IDK® Oncostatin M K 6926